Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2002 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 9, 2002
Last updated: December 18, 2013
Last verified: June 2002

RATIONALE: Some types of lymphoproliferative disease are associated with Epstein-Barr virus. Combining reduced immunosuppressive therapy with donor white blood cells that have been treated in the laboratory to kill cells infected with Epstein-Barr virus may be an effective treatment for lymphoproliferative disease.

PURPOSE: Randomized phase III trial to compare the effectiveness of reducing immunosuppressive therapy with or without donor white blood cells in treating patients who have Epstein-Barr virus-associated lymphoproliferative disease after organ transplantation.

Condition Intervention Phase
Lymphoproliferative Disorder
Biological: therapeutic allogeneic lymphocytes
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Complete response [ Designated as safety issue: No ]
  • Partial response [ Designated as safety issue: No ]
  • Stable disease [ Designated as safety issue: No ]
  • Progressive disease [ Designated as safety issue: No ]
  • Time to complete remission [ Designated as safety issue: No ]
  • Survival at 2 years [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2001
Detailed Description:


  • Determine the efficacy of treatment with partially HLA-matched allogeneic cytotoxic T cells and reduction of immunosuppression, in terms of survival rate and time to remission in patients with Epstein-Barr virus-associated B-cell lymphoproliferative disease after solid organ transplantation.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to transplanted organ type and transplant center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo sliding-scale reduction of immunosuppressive drugs from 1 of 5 regimens at physician's discretion. Patients then receive partially HLA-matched allogeneic cytotoxic T cells IV over 5 minutes once weekly for a total of 4 weeks.
  • Arm II: Patients undergo reduction of immunosuppression as in arm I alone. Patients are followed monthly for 6 months and then every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of post-transplant lymphoproliferative disease (PTLD) after solid organ (heart, heart/lung, liver, liver/gut, pancreas, or kidney) transplantation

    • Epstein-Barr virus-positive tumor
    • Newly diagnosed disease
  • Measurable disease by clinical methods or radiography
  • Must have partially matched donor cytotoxic T cells (CTL) available
  • No known panel reactivity to any of the HLA types of CTL available for therapy



  • Any age

Performance status:

  • Karnofsky 20-100%

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Not pregnant


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • No prior therapy for PTLD
  • No concurrent antiviral drugs (e.g., acyclovir or ganciclovir) for PTLD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00033475

United Kingdom
Birmingham Children's Hospital
Birmingham, England, United Kingdom, B4 6NH
Papworth Hospital
Cambridge, England, United Kingdom, CB3 8RE
Royal Free and University College Medical School
London, England, United Kingdom, NW3 2PF
King's College Hospital
London, England, United Kingdom, SE5 8RX
Central Manchester and Manchester Children's University Hospitals NHS Trust
Manchester, England, United Kingdom, M27 4HA
Wythenshawe Hospital
Manchester, England, United Kingdom, M23 9LJ
Northern General Hospital
Sheffield, England, United Kingdom, S5 7AU
Institute of Cancer Research - UK
Sutton, England, United Kingdom, SM2 5NG
Royal Infirmary of Edinburgh at Little France
Edinburgh, Scotland, United Kingdom, EH16 4SA
University of Edinburgh
Edinburgh, Scotland, United Kingdom, EH8 1QH
University of Edinburgh Laboratory for Clinical and Molecular Virology
Edinburgh, Scotland, United Kingdom, EH9 1QH
Royal Infirmary - Castle
Glasgow, Scotland, United Kingdom, G4 0SF
Sponsors and Collaborators
University of Edinburgh
Study Chair: Dorothy H. Crawford, MD University of Edinburgh
  More Information Identifier: NCT00033475     History of Changes
Other Study ID Numbers: CDR0000069288  CRUK-EBV-CTL  LCMV-CTL  EU-20057 
Study First Received: April 9, 2002
Last Updated: December 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
post-transplant lymphoproliferative disorder

Additional relevant MeSH terms:
Lymphoproliferative Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases processed this record on May 26, 2016